Bluer Than Blue

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

Retrieved on: 
Monday, November 22, 2021
Patient, Anesthesia, Adoption, CEO, Partner (business rank), Technology, Economics, Cardiology, Solution, Acute kidney injury, COVID-19, Vital signs, Critical care, ICU, AKI, Clarity, Risk, Health, Marketing, FDA, Bluer Than Blue, Growth, High-dependency unit, Medical device, Medical imaging

The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.

Key Points: 
  • The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.
  • The management team has been based in Asia and has been investing in and advising entrepreneurs for over 20 years.
  • The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics.
  • RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

Retrieved on: 
Monday, November 22, 2021
Patient, Anesthesia, Adoption, CEO, Partner (business rank), Technology, Economics, Cardiology, Solution, Acute kidney injury, COVID-19, Vital signs, Critical care, ICU, AKI, Clarity, Risk, Health, Marketing, FDA, Bluer Than Blue, Growth, High-dependency unit, Medical device, Medical imaging

The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.

Key Points: 
  • The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.
  • The management team has been based in Asia and has been investing in and advising entrepreneurs for over 20 years.
  • The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics.
  • RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.